EventsThe 1st International Online Conference on Clinical Reports
Published
This submission belongs to the session S1. Disaster/Climate Change Medicine of the event The 1st International Online Conference on Clinical Reports
Published date
17 Mar, 2025
Academic Editor
author-avatarIuliana Adelina Platon
Citation
Toshio Hattori, Hiroko Iwasaki-Hozumi, Toshiro Niki, Takashi Matsuba, Yosuke Maeda, Proteolyzed but not full-length galectin-9 in plasma predicts the prognosis of COVID-19, in Proceedings of The 1st International Online Conference on Clinical Reports, 19 March–20 March 2025, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Proteolyzed but not full-length galectin-9 in plasma predicts the prognosis of COVID-19

image
1. Department of Health Science and Social Welfare, Kibi International University, Japan
2. Department of Immunology, Faculty of Medicine, Kagawa University, Kita-gun, Japan, Japan
3. Department of Animal Pharmaceutical Science, School of Pharmaceutical Science, Kyusyu University of Health and Welfare, Japan
4. Department of Nursing, Kibi International University, Japan
5. Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka 420-0881, Japan, Japan
6. Graduate School of Public Health, Shizuoka Graduate University of Public Health
Abstract

INTRODUCTION

Increased circulating galectin-9 (Gal-9) is associated with COVID-19 severity. Gal-9 structurally consists of two homologous carbohydrate-recognition domains (NCRD and CCRD) linked by a linker peptide highly susceptible to proteolysis. Plasma Gal-9 NCRD with an attached truncated linker peptide (N-cleaved-Gal9) is a severity marker for COVID-19, indicating higher AUC than full-length (FL)-Gal9. This study aims to determine whether N-cleaved-Gal9 in plasma on admission serve as a reliable predictor of the hospitalization period in COVID-19.

METHODS

We examined 44 COVID-19 patients admitted to Sendai City Hospital. FL-Gal-9 ELISA and Tr-Gal9 ELISA measured FL-Gal9 and both Gal-9 containing NCRD (FL-Gal9 and N-cleaved-Gal9), respectively. N-cleaved-Gal9 levels were calculated by subtracting FL-Gal9 levels from Tr-Gal9 levels. The time course of FL-Gal-9 and N-cleaved-Gal9 levels from the day of admission to after discharge were monitored.

RESULTS

FL-Gal-9 and N-cleaved-Gal9 levels on admission positively correlated with the hospitalization period (r = 0.3964 and 0.5676, respectively). N-cleaved-Gal9 levels on admission in the hospitalization ≥ 7 days group were higher than those in the hospitalization ≤ 6 days and the levels in both groups converged to the same extent at discharge and after. N-cleaved-Gal9 (AUC = 0.7900) but not FL-Gal9 on admission significantly discriminated both groups, whereas CRP and P/F ratio on admission indicated AUC values of 0.7727 and 0.8268, respectively. The sensitivity of N-cleaved-Gal9 was higher than that of CRP. N-cleaved-Gal9 levels positively correlated with CRP levels during hospitalization but not at discharge and after suggesting Gal9 proteolysis is upregulated along with abnormal CRP. N-cleaved-Gal9 levels negatively correlated with P/F ratio only on admission, suggesting that Gal-9 proteolysis is associated with respiratory failure.

CONCLUSION

Plasma N-cleaved-Gal9 on admission predicted the hospitalization period more accurately than CRP in COVID-19 and demonstrated its performance by simultaneously measuring the CRP and P/F ratio. These findings contribute to the management of prognosis in COVID-19 although larger, more diverse cohorts are needed to validate the findings.

Keywords
COVID-19
Galectin-9
N-Cleaved-Gal9
Severity
Biomarker
Oral Presentation
Hyperbaric Oxygen Therapy to Enhance Functional Recovery in Bell’s Palsy: a Case Series
Molecular analysis of Fokl in the vitamin D receptor (VDR) and its effects on VDR mRNA and serum vitamin D concentrations in Uterine Leiomyoma among North Indian women: A case–control study.